Cas:26086-33-9 trimethylolpropane tris(2-ethylhexanoate) manufacturer & supplier

Chemical Name:trimethylolpropane tris(2-ethylhexanoate)

CAS.NO:26086-33-9

Synonyms:trimethylolpropane tri(2-ethyl hexanoate);TRIMETHYLOLPROPANE TRIETHYLHEXANOATE;Hexanoic acid,2-ethyl-,2-ethyl-2-(2-ethyl-1-oxohexyl)oxymethyl-1,3-propanediyl ester;1,1,1-Tris-hydroxymethyl-propan-tris-(2-ethyl-capronat)

Molecular Formula:C₃₀H₅₆O₆

Molecular Weight:512.76200

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:78.90000

Exact Mass:512.40800

LogP:7.66160

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like trimethylolpropane tri(2-ethyl hexanoate) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,1,1-Tris-hydroxymethyl-propan-tris-(2-ethyl-capronat) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,TRIMETHYLOLPROPANE TRIETHYLHEXANOATE Use and application,1,1,1-Tris-hydroxymethyl-propan-tris-(2-ethyl-capronat) technical grade,usp/ep/jp grade.

Related News: The company forecasts that the 70-strong team will grow by around 50% in the next three years to support its clinical and commercial API manufacturing capabilities. Acenaphtho[1′,2′:6,7]fluoreno[9,1,2-cde]benzo[rst]fluoreno[2,1,9-klm]pentaphene, 2,3-diethyl-1,4,11,18-tetraphenyl- manufacturers Building on this progress, recombinant technologies have been key to optimizing the performance of biocatalytic reagents, for example by facilitating a reduction in the amount of enzyme needed to drive a reaction while at the same time increasing the yield. (2-benzoyl-3,6-diphenylphenyl)-phenylmethanone suppliers (For more on Stevanato, see The Covid Vaccine Will Require Billions Of Tiny Glass Vials—And This Italian Billionaire Family Is Making Them.) Ethanone, 1-(2-methyl-1H-indol-3-yl)-2-phenyl-, oxime, (Z)- vendor & factory The company forecasts that the 70-strong team will grow by around 50% in the next three years to support its clinical and commercial API manufacturing capabilities. ,Building on this progress, recombinant technologies have been key to optimizing the performance of biocatalytic reagents, for example by facilitating a reduction in the amount of enzyme needed to drive a reaction while at the same time increasing the yield.